InVivoSIM anti-human GDF15 (Ponsegromab Biosimilar)

About InVivoSIM anti-human GDF15 (Ponsegromab Biosimilar)

This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody, Ponsegromab, making it ideal for research use. Ponsegromab targets GDF15, also known as growth differentiation factor 15, MIC-1, or NAG-1, a distant member of the transforming growth factor-beta (TGF-β) superfamily. GDF15 is a secreted cytokine that plays a critical role in energy homeostasis, appetite regulation, and the stress response. It is expressed at low levels under physiological conditions but is strongly upregulated in response to cellular stress, tissue injury, inflammation, and malignancy. Ponsegromab is a human IgG1 monoclonal antibody that binds with high specificity to circulating GDF15, thereby preventing its interaction with its cognate receptor, GFRAL, which is predominantly expressed in the area postrema and nucleus tractus solitarius of the brainstem. GDF15-GFRAL signaling has been implicated in the induction of anorexia and weight loss, particularly in chronic diseases such as cancer and heart failure. By blocking this pathway, Ponsegromab has been shown to reverse cachexia-associated anorexia in preclinical models. This antibody is useful for investigating the biological function of the GDF15-GFRAL axis, modeling therapeutic blockade of GDF15, and exploring the regulation of appetite and body weight in disease contexts. It may also be used to probe the immunometabolic consequences of stress-related cytokine signaling.